The Role of Beta2-Microglobulin in Central Nervous System Disease

Central nervous system (CNS) disorders represent the leading cause of disability and the second leading cause of death worldwide, and impose a substantial economic burden on society. In recent years, emerging evidence has found that beta2 -microglobulin (B2M), a subunit of major histocompatibility c...

Full description

Saved in:
Bibliographic Details
Published in:Cellular and molecular neurobiology 2024-12, Vol.44 (1), p.46, Article 46
Main Authors: Liu, Zhen-Yuan, Tang, Feng, Yang, Jin-Zhou, Chen, Xi, Wang, Ze-Fen, Li, Zhi-Qiang
Format: Article
Language:English
Subjects:
Alzheimer's disease
Animals
beta 2-Microglobulin - metabolism
Biomedical and Life Sciences
Biomedicine
Brain tumors
Cell Biology
Central nervous system
Central nervous system diseases
Central Nervous System Diseases - metabolism
Central Nervous System Diseases - pathology
Dementia disorders
HIV
Human immunodeficiency virus
Humans
Lymphoma
Major histocompatibility complex
Neurobiology
Neurodegenerative diseases
Neurosciences
Review Paper
Tumor microenvironment
β2 Microglobulin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Central nervous system (CNS) disorders represent the leading cause of disability and the second leading cause of death worldwide, and impose a substantial economic burden on society. In recent years, emerging evidence has found that beta2 -microglobulin (B2M), a subunit of major histocompatibility complex class I (MHC-I) molecules, plays a crucial role in the development and progression in certain CNS diseases. On the one hand, intracellular B2M was abnormally upregulated in brain tumors and regulated tumor microenvironments and progression. On the other hand, soluble B2M was also elevated and involved in pathological stages in CNS diseases. Targeted B2M therapy has shown promising outcomes in specific CNS diseases. In this review, we provide a comprehensive summary and discussion of recent advances in understanding the pathological processes involving B2M in CNS diseases (e.g., Alzheimer's disease, aging, stroke, HIV-related dementia, glioma, and primary central nervous system lymphoma).
ISSN:0272-4340
1573-6830
1573-6830
DOI:10.1007/s10571-024-01481-6